NZ747111A - Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan - Google Patents
Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphanInfo
- Publication number
- NZ747111A NZ747111A NZ747111A NZ74711115A NZ747111A NZ 747111 A NZ747111 A NZ 747111A NZ 747111 A NZ747111 A NZ 747111A NZ 74711115 A NZ74711115 A NZ 74711115A NZ 747111 A NZ747111 A NZ 747111A
- Authority
- NZ
- New Zealand
- Prior art keywords
- dextromethorphan
- bupropion
- compositions
- methods
- related compounds
- Prior art date
Links
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 title abstract 3
- 229960001985 dextromethorphan Drugs 0.000 title abstract 3
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 title abstract 2
- 229960001058 bupropion Drugs 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000002459 sustained effect Effects 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 2
- AKOAEVOSDHIVFX-UHFFFAOYSA-N Hydroxybupropion Chemical compound OCC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 AKOAEVOSDHIVFX-UHFFFAOYSA-N 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The disclosure relates to the use of a combination of dextromethorphan or a pharmaceutically acceptable salt thereof, and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a pharmaceutically acceptable salt thereof, for the treatment of pain or a neurological disorder via administration for eight consecutive days, wherein the dextromethorphan Cmax after the eighth consecutive day is between 6 ng/mL and 158.1 ng/mL and the AUC0-12 after the eighth consecutive day is greater than 700ng·hr/mL and less than 1,686.3 ng·hr/mL.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ764088A NZ764088A (en) | 2014-11-21 | 2015-05-01 | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
| NZ764077A NZ764077A (en) | 2014-11-21 | 2015-05-01 | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
| NZ764072A NZ764072A (en) | 2014-11-21 | 2015-05-01 | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/550,618 US9198905B2 (en) | 2013-11-05 | 2014-11-21 | Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects |
| US14/554,988 US9205083B2 (en) | 2013-11-05 | 2014-11-26 | Compositions and methods comprising erythrohydroxybupropion and related compounds for improving the efficacy of dextromethorphan |
| US14/554,947 US20150126542A1 (en) | 2013-11-05 | 2014-11-26 | Compositions and Methods for Increasing the Metabolic Lifetime of Dextromethorphan and Related Pharmacodynamic Effects |
| US14/555,085 US9238032B2 (en) | 2013-11-05 | 2014-11-26 | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
| US14/602,177 US9402843B2 (en) | 2013-11-05 | 2015-01-21 | Compositions and methods of using threohydroxybupropion for therapeutic purposes |
| US14/604,397 US9168234B2 (en) | 2013-11-05 | 2015-01-23 | Bupropion as a modulator of drug activity |
| US14/617,624 US9486450B2 (en) | 2013-11-05 | 2015-02-09 | Hydroxybupropion and related compounds as modulators of drug plasma levels |
| US14/628,062 US9402844B2 (en) | 2013-11-05 | 2015-02-20 | Methods of modulating drug plasma levels using erythrohydroxybupropion |
| NZ73214015 | 2015-05-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ747111A true NZ747111A (en) | 2023-06-30 |
Family
ID=87000456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ747111A NZ747111A (en) | 2014-11-21 | 2015-05-01 | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
Country Status (1)
| Country | Link |
|---|---|
| NZ (1) | NZ747111A (en) |
-
2015
- 2015-05-01 NZ NZ747111A patent/NZ747111A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4331677A3 (en) | Methods of treating feline coronavirus infections | |
| SG10201810888XA (en) | Compositions and methods comprising bupropion or related compounds and dextromethorphan | |
| PH12015502691A1 (en) | Use of high dose pridopidine for treating huntington's disease | |
| MX2022003072A (en) | Use of pridopidine for treating functional decline. | |
| MX2019003173A (en) | Combination therapy with controlled-release cnp agonists. | |
| NZ700881A (en) | Compositions and methods comprising celecoxib or related compounds and dextromethorphan | |
| MX2016009427A (en) | Modified release formulations of pridopidine. | |
| MX2024006689A (en) | Mono-(acid) salts of 6-aminoisoquinolines and uses thereof. | |
| PH12016502352A1 (en) | Pharmaceutical composition | |
| MX2024002360A (en) | USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONRIAL DISORDERS. | |
| MX2022000143A (en) | Novel methods. | |
| MX2019006773A (en) | Dexmedetomidine or medetomidine for use in treating separation anxiety in dogs. | |
| MX2019012522A (en) | Therapeutic compounds and methods. | |
| MY192813A (en) | Aqueous formulation comprising paracetamol and ibuprofen | |
| MX2016016400A (en) | Stabilized oxymetazoline formulations and their uses. | |
| MX2018011592A (en) | Compound having mutant idh inhibitory activity, preparation method and use thereof. | |
| PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
| MX2016010892A (en) | Agent for improving or preventing progression of chronic kidney disease. | |
| MX2019003039A (en) | Extended relief dosage form. | |
| SG10201809673RA (en) | Treatment of androgen deprivation therapy associated symptoms | |
| MX2016014740A (en) | A method for treating movement disorders with befiradol. | |
| NZ712584A (en) | Antitumor agent including irinotecan hydrochloride hydrate | |
| NZ747111A (en) | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan | |
| TW201613606A (en) | Therapeutic drug for chronic renal failure | |
| NZ764088A (en) | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAY 2025 BY ANAQUA SERVICES Effective date: 20240418 |